175 related articles for article (PubMed ID: 25142821)
1. Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.
Baltzley S; Mohammad A; Malkawi AH; Al-Ghananeem AM
AAPS PharmSciTech; 2014 Dec; 15(6):1598-602. PubMed ID: 25142821
[TBL] [Abstract][Full Text] [Related]
2. Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies.
Abdelbary GA; Tadros MI
Int J Pharm; 2013 Aug; 452(1-2):300-10. PubMed ID: 23684658
[TBL] [Abstract][Full Text] [Related]
3. Sublingual spray drug delivery of ketorolac-loaded chitosan nanoparticles.
Baltzley S; Malkawi AA; Alsmadi M; Al-Ghananeem AM
Drug Dev Ind Pharm; 2018 Sep; 44(9):1467-1472. PubMed ID: 29607693
[TBL] [Abstract][Full Text] [Related]
4. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses.
Al-Ghananeem AM; Saeed H; Florence R; Yokel RA; Malkawi AH
J Drug Target; 2010 Jun; 18(5):381-8. PubMed ID: 20001275
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.
Seju U; Kumar A; Sawant KK
Acta Biomater; 2011 Dec; 7(12):4169-76. PubMed ID: 21839863
[TBL] [Abstract][Full Text] [Related]
6. Formulation and characterization of nanoemulsion of olanzapine for intranasal delivery.
Kumar M; Misra A; Pathak K
PDA J Pharm Sci Technol; 2009; 63(6):501-11. PubMed ID: 20169856
[TBL] [Abstract][Full Text] [Related]
7. "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Shah B; Khunt D; Misra M; Padh H
Int J Biol Macromol; 2016 Aug; 89():206-18. PubMed ID: 27130654
[TBL] [Abstract][Full Text] [Related]
8. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
[TBL] [Abstract][Full Text] [Related]
9. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
10. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
11. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting.
Kumar M; Misra A; Mishra AK; Mishra P; Pathak K
J Drug Target; 2008 Dec; 16(10):806-14. PubMed ID: 18988064
[TBL] [Abstract][Full Text] [Related]
12. Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route.
Salama HA; Mahmoud AA; Kamel AO; Abdel Hady M; Awad GA
Colloids Surf B Biointerfaces; 2012 Dec; 100():146-54. PubMed ID: 22766291
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of brain targeting efficiency of intranasal microemulsion containing olanzapine: pharmacodynamic and pharmacokinetic consideration.
Patel RB; Patel MR; Bhatt KK; Patel BG; Gaikwad RV
Drug Deliv; 2016; 23(1):307-15. PubMed ID: 24845478
[TBL] [Abstract][Full Text] [Related]
14. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study.
Qureshi M; Aqil M; Imam SS; Ahad A; Sultana Y
Curr Drug Deliv; 2019; 16(2):123-135. PubMed ID: 30317997
[TBL] [Abstract][Full Text] [Related]
15. Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats.
Dimer FA; Pigatto MC; Boque CA; Pase CS; Roversi K; Pohlmann AR; Burger ME; Rates MK; Dalla Costa T; Guterres SS
J Biomed Nanotechnol; 2015 Aug; 11(8):1482-93. PubMed ID: 26295148
[TBL] [Abstract][Full Text] [Related]
16. Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use.
Asasutjarit R; Theerachayanan T; Kewsuwan P; Veeranodha S; Fuongfuchat A; Ritthidej GC
AAPS PharmSciTech; 2015 Oct; 16(5):1013-24. PubMed ID: 25609376
[TBL] [Abstract][Full Text] [Related]
17. Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles.
Di Gioia S; Trapani A; Mandracchia D; De Giglio E; Cometa S; Mangini V; Arnesano F; Belgiovine G; Castellani S; Pace L; Lavecchia MA; Trapani G; Conese M; Puglisi G; Cassano T
Eur J Pharm Biopharm; 2015 Aug; 94():180-93. PubMed ID: 26032293
[TBL] [Abstract][Full Text] [Related]
18. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
19. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
[TBL] [Abstract][Full Text] [Related]
20. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
